SHR-1916: A Novel PEGylated Interleukin-2 Analogue with Altered Cellular Selectivity and Improved Pharmacokinetic Profiles for Cancer Immunotherapy
SHR-1916 exhibited excellent cellular selectivity, anti-tumor efficacies, and improved pharmacokinetics. It has the potential to serve as a novel immunotherapeutic agent designed to enhance IL-2's immune-stimulating activities and promote its tolerability while reducing the immunoregulatory function of T<sub>reg</sub> cells.
Authors
- Chen Ouyang (ORCID: https://orcid.org/0000-0003-1387-9408)
- Yuan Lin (ORCID: https://orcid.org/0000-0002-6263-782X)
- Xiangdong Gao (ORCID: https://orcid.org/0000-0001-6864-7407)
- Xianglin Kong
- Hao Chen (ORCID: https://orcid.org/0000-0003-3173-3832)
Institutions
- China Pharmaceutical University (CN)
- Jiangsu Hengrui Medicine (China) (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/dddt.s493011
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 6.27